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Surveillance Network Work Group1
We conducted a population-based study to assess demographic and risk-factor correlates for the most fre-
quently occurring Mycobacterium tuberculosis genotypes from tuberculosis (TB) patients. The study
included all incident, culture-positive TB patients from seven sentinel surveillance sites in the United States
from 1996 to 2000. M. tuberculosis isolates were genotyped by IS6110-based restriction fragment length
polymorphism and spoligotyping. Genotyping was available for 90% of 11,923 TB patients. Overall, 48% of
cases had isolates that matched those from another patient, including 64% of U.S.-born and 35% of for-
eign-born patients. By logistic regression analysis, risk factors for clustering of genotypes were being
male, U.S.-born, black, homeless, and infected with HIV; having pulmonary disease with cavitations on
chest radiograph and a sputum smear with acid-fast bacilli; and excessive drug or alcohol use. Molecular
characterization of TB isolates permitted risk correlates for clusters and specific genotypes to be described
and provided information regarding cluster dynamics over time.
ince 1990, characterization of Mycobacterium tuberculosis
isolates by molecular methods has been useful in confirm-
ing suspected laboratory contamination and as an adjunct to
epidemiology-based contact investigation (1–3). Most studies
used the restriction fragment length polymorphism (RFLP)
technique, based on IS6110 and specific to the M. tuberculosis
complex. This genetic element may be present in different
positions on the chromosome, resulting in a unique genotype
useful for characterizing the strain of M. tuberculosis infecting
a patient. Although RFLP has disadvantages (e.g., cost, time
required to culture the organism, and specialized training and
laboratory equipment), IS6110-based RFLP is the established
method considered most discriminatory for genetic character-
ization of M. tuberculosis strains worldwide (4).
In 1996, the Centers for Disease Control and Prevention
(CDC) established seven sentinel surveillance sites in the
United States (National Tuberculosis Genotyping and Surveil-
lance Network) to assess the utility of molecular genotyping
for improving tuberculosis (TB) prevention and control. The
TB genotyping network used standardized protocols for
molecular characterization of M. tuberculosis isolates from
patients in all sentinel sites. The network  was designed to
address specific epidemiologic questions regarding the natural
history, transmission, and potential applicability of molecular
genotyping of M. tuberculosis strains to augment TB control
activities (5). Two objectives were to identify and determine
the prevalence of specific M. tuberculosis genotype clustering
in populations of sentinel surveillance TB patients and to
describe the demographic characteristics of these populations
and the genotypic characteristics of M. tuberculosis strains in
clustered and nonclustered TB cases. We describe demo-
graphic and risk factor correlates for the most frequently
occurring M. tuberculosis genotypes in isolates collected from
sentinel TB patients.
Methods
This population-based sentinel study included all incident
culture-positive TB patients from sentinel sites from January
1996 to December 2000. In brief, the seven sentinel surveil-
lance sites included the states of Arkansas, Maryland, Massa-
chusetts, Michigan, and New Jersey; Dallas, Tarrant,
Cameron, and Hidalgo Counties in Texas; and Alameda, Con-
tra Costa, Marin, San Mateo, Santa Clara, and Solano Counties
in California. A detailed description of the study’s design, par-
ticipants, population, and laboratory and epidemiologic meth-
ods is provided elsewhere (6).
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All patients included in the study were reported to the
CDC national TB case registry on the form Report of a Veri-
fied Case of Tuberculosis, a standardized electronic form sub-
mitted for TB surveillance to CDC by all state public health
reporting areas. Data reported include patient demographics,
laboratory test results, drug susceptibilities, information on
chest radiographs, and treatment outcomes (7).
Investigators from the sentinel surveillance sites submitted
patient isolates to the corresponding regional laboratory for
genotyping and conducted routine contact investigations. In
addition, participants from the surveillance sites performed
detailed epidemiologic investigations on groups of persons
with M. tuberculosis isolates that had matching genetic pat-
terns or clusters (see below). The regional genotyping labora-
tories conducted IS6110 RFLP on isolates from sentinel
patients. Since low-copy numbers of IS6110 (i.e., six or fewer
copies) reduce test specificity, spacer oligonucleotide typing
(spoligotyping) was conducted on such isolates. A cluster,
which was identified by analysis of the entire TB genotyping
network database, was defined as two or more isolates with
either identical RFLP patterns (at least seven copies of IS6110)
or identical RFLP and spoligotype patterns for isolates with
RFLP patterns that had six or fewer copies of IS6110.
Differences in the proportion of TB patients from the TB
genotyping network population living in cities with populations
of <100,000, 100,001 to 250,000, 250,001 to 500,000, and
>500,000 were compared with those of the national TB patients
for the year 2000 only. Statistics were obtained from the U.S.
Census Bureau (available at: URL: http://www.census.gov/
population/cen2000/phc-t6/tab04.pdf ).
Correlation of average TB incidence among cases at the
seven sentinel sites and percentage of cases with isolates that
clustered genetically were examined by year by using the
Spearman rank correlation statistic. Clustering was determined
by examining each year’s cases independently. A Mantel-
Haenszel chi-square or Fisher exact test was used, as appropri-
ate, to ascertain whether the sentinel population was represen-
tative of TB patients in the United States in terms of
demographic, clinical, behavioral, or outcome characteristics.
We used multiple logistic regression to assess the impor-
tance of demographic, clinical, behavioral, or outcome vari-
ables in predicting the occurrence of a given genotype for
those genetic clusters that occurred most frequently (≥ 20 iso-
lates). The dependent variable was the presence or absence of
a given genotype. The best-fit logistic regression model was
determined by the strategy of Hosmer and Lemeshow (8). In
brief, a univariate analysis of the categorical independent vari-
ables was done by using the Mantel-Haenszel chi-square or
Fisher exact test, as appropriate; any variable with a signifi-
cance value of ≥ 0.20 was included in a best subset, multivari-
ate logistic regression model. Collinearity  of independent
variables was assessed by using the variance/covariance
matrix from PROC LOGISTIC (SAS Institute, Inc., Cary, NC)
to generate condition indices and a matrix of variance decom-
position proportions to detect dependencies among the vari-
ables (9). Backward elimination of independent variables was
performed if the probability of the independent variable was
≥ 0.20. Both the Wald statistic and 95% confidence interval
were used on each coefficient to assess the significance of
variables in each model; the log-likelihood ratio was used to
assess the overall significance of the final models, and the
Hosmer-Lemeshow statistic was used to evaluate the fit of
each of the final models. Data were analyzed by SAS version
8.0 software (SAS Institute, Inc.) (10).
Results
Sentinel Population Characteristics
The incidence of TB cases in the sentinel surveillance sites
varied within and among sites over time (Table 1). From 1996
to 2000, the overall incidence of TB in the United States
declined from 8.0 to 5.8 per 100,000 inhabitants, and similar
downward trends were observed in each of the TB genotyping
network sites. The California, New Jersey, Arkansas, and
Texas sites had a higher incidence of TB than the overall
national rates. The incidence rates in California and Texas
(sites that included only six and four counties from each state)
were similar to the overall incidence rates for each state (data
not shown).
In the surveillance area, 15,035 patients with verified TB
represented 16% of the TB patients in the United States during
the 5-year study period (Table 2). Overall, 11,923 TB patients
were culture-positive (721 from Arkansas, 2,842 from
California, 1,192 from Maryland, 1,022 from Massachusetts,
1,481 from Michigan, 2,599 from New Jersey, and 2,066 from
Texas). Of TB patients in the surveillance areas, 79.3%
(11,923) were culture positive, and RFLP results were avail-
able for 91.2% (10,883). However, spoligotyping results were
not available for 131 of the isolates that had six or fewer cop-
ies of IS6110 (5%; n=2,638); thus, these patients were
excluded from our analysis. Of 1,171 isolates not genotyped
by RFLP or spoligotyping, 12 (1%) were from Michigan, 35
(3%) from Maryland, 40 (3%) from Massachusetts, 110 (9%)
Table 1. Incidence of tuberculosis cases in the United States and in 
the sentinel surveillance areas of the National Tuberculosis Genotyp-
ing Surveillance Network, 1996–2000a
Sentinel surveillance site 1996 1997 1998 1999 2000 Mean
Arkansas 9.0 7.9 6.7 7.1 7.4 7.6
Californiab 16.3 13.9 13.9 12.9 11.6 13.7
Maryland 6.3 6.7 6.3 5.7 5.3 6.1
Massachusetts 4.3 4.4 4.6 4.4 4.5 4.4
Michigan 4.6 3.8 3.9 3.6 2.9 3.8
New Jersey 10.3 8.9 7.9 7.0 6.7 8.2
Texasb 12.7 12.8 12.5 10.9 9.6 11.7
United States 8.0 7.4 6.8 6.4 5.8 6.9
aNumber per 100,000 inhabitants.
bSentinel surveillance areas for California and Texas did not include the entire states.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1199
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from Arkansas, 156 (13%) from Texas, 327 (28%) from Cali-
fornia, and 491 (42%) from New Jersey. Primary reasons for
lack of genotyping results included inability to obtain cultures
from private health-care providers, contamination of cultures,
or poorly growing or nonviable cultures.
Characteristics of the TB patient population from the geno-
typing network sentinel sites were comparable with those from
the entire United States, with some exceptions (Table 2). Senti-
nel surveillance populations had higher proportions of women
(42% for the genotyping network vs. 37% for the United States
overall) and patients in the 15- to 44-year age category, and
were more often homeless or lived in correctional or long-term
care facilities. Higher proportions of genotyping network
patients used intravenous drugs, but fewer patients used nonin-
jecting drugs or alcohol excessively. 
Of the study population, about 4% reported previous epi-
sodes of TB (652 of 15,035; Table 2). Of persons with a previ-
ous recent history of TB, 28 had TB after completing >1 year
of therapy within the study period; genotyping data on isolates
from both episodes were available for 22 of these persons. A
higher number of persons from the TB genotyping network
study population lived within city limits (97% vs. 87%). How-
ever, when compared with national averages, genotyping net-
work populations were generally from smaller towns and
cities: 1,446 (69%) of 2,099 genotyping network patients were
from cities and towns with <250,000 inhabitants, compared
with 10,093 (62%) of 16,377 TB patients nationwide (Mantel-
Haenszel chi square= 41.8; p<0.0001).
The proportion of foreign-born patients was higher in
genotyping network populations compared with the overall
national average (50% for genotyping network vs. 41% for the
United States). Numbers of foreign-born TB patients increased
over time at about the same rate for both genotyping network
populations and national TB patients. From 1996 to 2000,
national proportions of foreign-born TB patients increased
from 37% (7,725/21,045) to 47% (7,593/16,281); in the geno-
typing network populations, the proportions of foreign-born
TB patients increased from 44% (1,153/2,642) to 58% (1,222/
2,092). Characteristics of the genotyping network population
between sites were similar, as were culture-positive genotyp-
ing network populations compared with the overall genotyping
network case population.  
Analysis of Genotyping Data
The distribution and diversity of RFLP and spoligotyping
pattern results from the genotyping network have been dis-
cussed in detail (11). In contrast to that analysis, we used both
RFLP and spoligotyping results to define genetic clusters.
Overall, 6,609 distinct patterns were identified, including
1,029 that contained ≥ 2 isolates per cluster. When analyzed by
site, 1,018 clusters were identified: 71 clusters were from
Arkansas (611 cases genotyped, 2–16 cases per cluster), 233
from California (2,511 cases, 2–128 cases per cluster), 104
from Maryland (1,157 cases, 2–36 cases per cluster), 85 from
Massachusetts (982 cases, 2–16 cases per cluster), 125 from
Michigan (1,469 cases, 2–102 cases per cluster), 196 from
New Jersey (2,112 cases, 2–40 cases per cluster), and 204
from Texas (1,910 cases, 2–96 cases per cluster). Overall, 970
distinct genotypes, including 235 representing clusters, had ≤ 6
copies (2,507 cases, 24% clustered, 2–93 cases per cluster). In
contrast, 794 clusters from 5,639 distinct genotypes had ≥  7
IS6110 copies (8,245 cases, 14% clustered, 2–105 cases per
cluster). Most clusters included seven or fewer persons (85%;
900/1,029). 
Longitudinal Analysis
Most clusters occurred in only a single site (66%; 680/
1,029). However, 260 (25%) were found in two sites, 55 (5%)
in three sites, 19 (2%) in four, 8 (1%) in five, and 7 (1%) in six
sites. As expected, clusters that spanned multiple sites were
larger. Clusters found at a single site averaged four persons per
cluster (mean=3.65; standard error [SE] ± 0.22; n=680), in
contrast to 61 persons per cluster for the genotypes found at
six sites (mean=61.14; SE ± 23.6; n=7; Kruskal-Wallis test,
p<0.0001). Most (62%) of the 34 clusters that occurred in at
least four sites occurred in all 5 years of the study; 26% in 4
years; and 6% each in 3 and 2 years of the study. 
Changes in proportions of patients with isolates that clus-
tered were observed over time. In the first 2 years of the study,
the percentage of the cumulative total number of cases that
clustered increased from 28% to 45%; smaller increases
occurred thereafter (Figure 1). Overall, the proportion of clus-
tered cases was 48% (5,171/10,752). The percentages of clus-
tered cases by sites were 28% (276/982) for Massachusetts;
34% (393/1,157) for Maryland; 41% (873/2,112) for New Jer-
sey; 42% (1,046/2,511) for California; 44% (266/611) for
Arkansas; 49% (720/1,469) for Michigan; and 57% (1,093/
1,910) for Texas. Maximum cluster size and absolute numbers
of cases with isolates that clustered continued to increase
through the end of the study.
Overall, cases with isolates that clustered showed a con-
comitant decline with average incidence of TB over the 5-year
period (Figure 2). A significant positive association was
observed between the percentage of cases with clustered geno-
types and TB incidence over time (Spearman rho=0.90;
p=0.037).
Risk Factor Analyses of Genetic Clusters
Compared with persons whose isolates had unique geno-
types, persons with isolates that clustered were more likely to
be non-Hispanic, black men born in the United States. They
were more likely to have pulmonary disease and abnormal
chest radiographs with cavities; in addition, they more often
had positive sputum smears; were HIV-positive, homeless, or
residents of a correctional facility; and used drugs or alcohol
excessively (Table 3). Patients with unclustered isolates were 5
years older on the average than those with isolates that clus-
tered (44.8 years vs. 49.4 years, respectively; Table 3). Multi-
ple logistic regression efforts resulted in models that were not
robust (data not shown).TUBERCULOSIS GENOTYPING NETWORK
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Table 2. Demographic and risk behavior factors and clinical, laboratory, and treatment outcomes for the sentinel surveillance patients (National 
Tuberculosis Genotyping and Surveillance Network) compared with factors and outcomes of all tuberculosis patients, United States, 1996–2000a,b
Variable Category
All U.S. TB cases 
(n=93,097) (%)
All NTGSN cases 
(n=15,035) (%) Probabilityc
Gender Male 58,356 (62.7) 8,767 (58.3) <0.001
Female 34,734 (37.3) 6,266 (41.7)
Unknown 7 (0.0) 2 (0.0)
Age (yrs) <4 3,289 (3.5) 518 (3.4) NS
5–14 2,397 (2.6) 393 (2.6) NS
15–24 7,988 (8.6) 1,462 (9.7) <0.001
25–44 32,433 (34.8) 5,413 (36.0) 0.005
45–64 25,319 (27.2) 3,850 (25.6) <0.001
>64 21,662 (23.3) 3,397 (22.6) NS
Unknown 9 (0.0) 2 (0.0)
Race/ethnicity White, non-Hispanic 22,655 (24.3) 3,087 (20.5) <0.001
Black, non-Hispanic 30,201 (32.4) 4,775 (31.8) NS
Hispanic 20,475 (22.0) 2,923 (19.4) <0.001
American Indian/Native 1,280 (1.4) 38 (0.3) <0.001
Asian/Pacific Islander 18,346 (19.7) 4,195 (27.9) <0.001
Unknown 140 (0.2) 17 (0.1)
Place of birth U.S.-born 54,341 (58.4) 7,530 (50.1) <0.001
Foreign-born 38,252 (41.1) 7,468 (49.7)
Unknown 504 (0.5) 37 (0.2)
Years in United States (foreign-born only) <1 7,425 (19.4) 1,494 (20.0) NS
1 2,612 (6.8) 567 (7.6) NS
2 2,073 (5.4) 477 (6.4) <0.005
3 1,827 (4.8) 406 (5.4) <0.05
4 1,676 (4.4) 361 (4.8) NS
>5 19,396 (50.7) 3,688 (49.4) <0.001
Unknown 3,243 (8.5) 475 (6.4)
Country of origind Philippines 4,862 (12.7) 1,113 (14.9) <0.0001
Mexico 8,795 (23.0) 1,100 (14.7) <0.0001
Vietnam 3,824 (10.0) 968 (13.0) <0.0001
India 2,527 (6.6) 883 (11.8) <0.0001
China 1,930 (5.0) 370 (5.0) NS
Haiti 1,470 (3.8) 225 (3.0) <0.0005
Peru 636 (1.7) 207 (2.8) <0.0001
Republic of Korea 1,176 (3.1) 202 (2.7) NS
Ethiopia 578 (1.5) 153 (2.0) <0.001
Ecuador 627 (1.6) 115 (1.5) NS
Other 11,827 (30.9) 2,132 (28.5) <0.0001
Status at diagnosis Alive 90,141 (96.8) 14,611 (97.2) 0.02
Dead 2,925 (3.1) 422 (2.8)
Unknown 31 (0.0) 2 (0.0)
Site of disease Pulmonary 68,611 (73.7) 10,576 (70.3) <0.001Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1201
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Table 2. (continued) Demographic and risk behavior factors and clinical, laboratory, and treatment outcomes for the sentinel surveillance 
patients (National Tuberculosis Genotyping and Surveillance Network) compared with factors and outcomes of all tuberculosis patients, United 
States, 1996–2000a,b
Variable Category
All U.S. TB cases 
(n=93,097) (%)
All NTGSN cases 
(n=15,035) (%) Probabilityc
Site of disease Extrapulmonary 17,406 (18.7) 3,210 (21.4) <0.001
Pulmonary and Extrapulmonary 7,046 (7.6) 1,241 (8.3) 0.003
Unknown 34 (0.0) 8 (0.1)
Primary disease site Pulmonary 73,157 (78.6) 11,365 (75.6) <0.0001
Lymph: cervical 4,312 (4.6) 1,020 (6.8) <0.0001
Pleural 3,842 (4.1) 674 (4.5) <0.05
Primary disease site Miliary 1,407 (1.5) 241 (1.6) NS
All other 10,345 (11.1) 1,727 (11.5) NS
Unknown 34 (0.0) 8 (0.0)
Sputum smear for acid-fast organisms Negative 36,912 (39.6) 5,995 (39.9) <0.0001
Positive 33,235 (35.7) 4,735 (31.5)
Not done/unknown 22,950 (24.6) 4,305 (28.7)
TST at diagnosis Negative 13,215 (14.2) 1,947 (12.9) <0.001
Positive 54,113 (58.1) 8,799 (58.5)
Not done/unknown 25,769 (27.6) 4,289 (28.6)
Case verification criteria Positive culture 74,940 (80.5) 11,967 (79.6) <0.01
Positive smear 765 (0.8) 136 (0.9) NS
Clinical case 11,286 (12.1) 1,858 (12.4) NS
Provider diagnosis 6,106 (6.6) 1,074 (7.1) <0.01
Chest radiographe Cavitary 18,742 (24.8) 2,990 (25.3) NS
Noncavitary 50,652  (66.9) 7,897  (66.8) NS
Normal 2,495 (3.3) 360 (3.0) NS
Not done/unknown 3,802 (5.0) 578 (4.9)
Total 75,691 11,825
HIV statusf  Positive 6,062 (18.8) 884 (16.7) NS
Negative 16,525 (51.2) 2,406 (45.5)
Indeterminate 47 (0.1) 6 (0.1)
Refused 1,959 (6.1) 325 (6.1)
Not offered 4,130 (12.8) 899 (17.0)
Test done, unknown 714 (2.2) 115 (2.2)
Unknown 2,812 (8.7) 658 (12.4)
Total 32,249 5,293
Homeless within past year Yes 5,789 (6.2) 646 (4.3) <0.001
No 84,873 (91.2) 14,185 (94.3)
Unknown 2,435 (2.6) 204 (1.4)
Resident of correctional facility at diagnosis Yes 3,352 (3.6) 377 (2.5) <0.001
No 89,479 (96.1) 14,617 (97.2)
Unknown 266 (0.3) 41 (0.3)
Correctional facility type Federal prison 164 (4.9) 6 (1.6) <0.005
State prison 1,036 (30.9) 97 (25.7) <0.05TUBERCULOSIS GENOTYPING NETWORK
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Table 2. (continued) Demographic and risk behavior factors and clinical, laboratory, and treatment outcomes for the sentinel surveillance 
patients (National Tuberculosis Genotyping and Surveillance Network) compared with factors and outcomes of all tuberculosis patients, United 
States, 1996–2000a,b
Variable Category All U.S. TB cases 
(n=93,097) (%)
All NTGSN cases 
(n=15,035) (%)
Probabilityc
Correctional facility type Total 3,352 377
Local jail 1,905 (56.8) 231 (61.3) NS
Juvenile facility 33 (1.0) 8 (2.1) NS
Other 161 (4.8) 34 (9.0) <0.001
Unknown 53 (1.6) 1 (0.3)
Yes 3,157 (3.4) 441 (2.9) 0.004
Resident, long-term care facility at diagnosis Unknown 284 (0.3) 42 (0.3)
Long-term care facility type Nursing home 1,794 (56.8) 279 (63.3) <0.01
Hospital-based 441 (14.0) 66 (15.0) NS
Residential 356 (11.3) 34 (7.7) <0.05
All other 504 (16.0) 55 (12.5) NS
Unknown 62 (2.0) 7 (1.6)
Total 3,157 441
Injecting drug useg Yes 2,569 (2.8) 515 (3.4) <0.001
No 83,141 (89.3) 13,771 (91.6)
Unknown 7,387 (7.9) 749 (5.0)
Noninjecting drug useg Yes 6,557 (7.0) 811 (5.4) <0.001
No 78,622 (84.5) 13,367 (88.9)
Unknown 7,918 (8.5) 857 (5.7)
Excessive alcohol useh Yes 13,646 (14.7) 1,661 (11.0) <0.001
No 71,924 (77.3) 12,552 (83.5)
Unknown 7,527 (8.1) 822 (5.5)
Drug resistancei
First-line drugs Yes 8,456 (11.7) 1,482 (12.6) <0.001
No 57,029 (79.0) 8,886 (75.5)
Not tested/unknown 6,703 (9.3) 1,399 (11.9)
Total 72,188 11,767
Second-line drugs Yes 1,341 (1.9) 208 (1.8) <0.001
No 175 (0.2) 78 (0.7)
Not tested/unknown 70,672 (97.9) 11,481 (97.6)
Total 72,188 11,767
DOT Yes—total DOT 40,511 (43.5) 4,936 (32.8) <0.001
Yes—both DOT and self-administered 20,555 (22.1) 3,648 (24.3) <0.001
No 23,337 (25.1) 5,326 (35.4) <0.001
Unknown 8,694 (9.3) 1,125 (7.5)
Within city limits Yes 80,775 (86.8) 14,603 (97.1) <0.001
No 10,916 (11.7) 374 (2.5)
Unknown 1,406 (1.5) 58 (0.4)
Previous diagnosis of TB Yes 4,794 (5.1) 652 (4.3) <0.001
No 87,567 (94.1) 14,336 (95.4)Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1203
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Except for 4 genotypes, all 34 clusters with ≥  20 isolates
per cluster had significant demographic, clinical, and behav-
ioral risk factors (Table 4). Race, ethnicity, and place of birth
were frequently significant predictors for a given genotype.
Other predictors included gender, age, site of disease, resis-
tance to first-line drugs, and alcohol or drug abuse (Table 4).
Twelve (40%) of 30 of these larger clusters were observed in
four or more sites over a 5-year period. Lower percentages of
foreign-born patients than U.S.-born patients clustered, regard-
less of the number of IS6110 copies (Figure 3). More than 50%
(1,025/1,825) of the foreign-born patients whose isolates clus-
tered had been in the United States for ≥ 5 years. Clustering of
isolates from foreign-born patients ranged from 15% (49/316)
in Michigan to 38% (309/816) in Texas. 
Discussion
This population-based study is the largest that has been
conducted in the United States to assess risk factors related to
specific M. tuberculosis genotypes. Generally, clustered iso-
lates have been considered recently acquired infections (12).
However, this assumption may not always be correct. Cluster-
ing does not prove that transmission occurred, and its demon-
stration depends on adequate sampling of the population,
incidence of TB, and characteristics of the study population
(e.g., age structure, population mobility, duration of residence,
and immune status) (1,13). Only 25%–42% of patients in
genetic clusters were shown to have epidemiologic connec-
tions with another member of the cluster (14–16). Conven-
tional epidemiologic investigation of these TB patients
(including interviews) was conducted, but inclusion in this
analysis was outside the scope of this article. Thus, results that
indicate clustered genotypes are representative of recent trans-
mission should be interpreted with caution.
Given this caveat, our results nevertheless demonstrate
several consistent patterns. Differences in demographic and
other risk factors for persons with isolates that clustered cor-
roborated those from smaller studies conducted in the United
States and larger surveys in Europe. Extensive surveys from
Figure 1. Numbers of tuberculosis cases, cumula-
tive proportion of cases with isolates in genetic clus-
ters, and maximum genetic cluster size from seven
sentinel surveillance sites by quarter that verified
case was counted, 1996–2000. Numbers of cases
with isolates that had unique genotypes and those
with isolates that were in genetic clusters are shown
separately.
Table 2. (continued) Demographic and risk behavior factors and clinical, laboratory, and treatment outcomes for the sentinel surveillance 
patients (National Tuberculosis Genotyping and Surveillance Network) compared with factors and outcomes of all tuberculosis patients, United 
States, 1996–2000a,b
Variable Category All U.S. TB cases (n=93,097) (%) All NTGSN cases (n=15,035) (%) Probabilityc
Previous diagnosis of TB Unknown 736 (0.8) 47 (0.3
Duration of therapy (days) Mean 246 245 NS
Median 217 214
Std. dev. 135 130
No. 65,344 10,822
aNTGSN, National Tuberculosis Genotyping Surveillance Network;TB, tuberculosis; DOT, directly observed therapy; TST, tuberculin skin test; Std. dev., standard deviation; NS, not 
significant (p>0.05).
bSubtotals for each category are listed if different from the total case numbers.
cProbability of significant differences between U.S. TB patients and all NTGSN surveillance patients (chi-square test; t-test for duration of therapy); referent group is all other groups 
combined, excluding not done or unknown categories, unless otherwise noted.
dTop 10 countries for foreign-born patients only.
eExcludes cases with extrapulmonary TB only.
fHIV cases from California are excluded because this site does not report HIV results on Report of a Verified Case of Tuberculosis forms; ages 15–44 years only.
gInjecting or noninjecting drug use within last year; includes use of licensed, prescription, or illegal drugs (not prescribed by a physician).
hExcessive use of alcohol within the past year as indicated by participation in alcohol treatment programs, diagnosis of alcoholism, or observation of intoxication during visits to 
health-care facilities.
iDrug resistance on initial testing of isolate. First-line drug resistance is resistance to at least one of the following: isoniazid, rifampin, ethambutol, or streptomycin. Second-line drug 
resistance is resistance to one or more of the following: ethionamide, kanamycin, cycloserine, capreomycin, para-amino salicylic acid, amikacin, rifabutin, ciprofloxacin, ofloxacin, or 
other drugs. Testing results for one or more of the drugs could have been missing.TUBERCULOSIS GENOTYPING NETWORK
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Table 3. Comparison of demographic and behavioral risk factors and clinical and treatment outcomes of tuberculosis (TB) case-patients who 
have genetically clustered genotypes with factors and outcomes of patients who had unique genotype patternsa
Variableb Clustered (%) Unclustered (%) Relative risk (95% CI) Probabilityc
Total cases (n=10,752) 5.171(48.1) 5,581(51.9)
Gender Male 3,289 (63.6) 3,107 (55.7) 1.19 (1.14% to 1.24%) <0.001
Female 1,881 (36.4) 2,473 (44.3)
Unknown 1 (0.0) 1 (0.0)
Mean age (yrs; ±S.E.) 44.8 (±0.26) 49.4 (±0.28)  <0.0001
Race/ethnicity White, non-Hispanic 1,018 (19.7) 1,201 (21.5) 0.94 (0.90% to 0.99%) 0.02
Black, non-Hispanic 2,254 (43.6) 1,237 (22.2) 1.61 (1.55% to 1.67%) <0.001
Hispanic 914 (17.7) 1,112 (19.9) 0.92 (0.88% to 0.97%) 0.003
American Indian/Native 17 (0.3) 10 (0.2)
Asian/Pacific Islander 961 (18.6) 2,014 (36.1) 0.60 (0.56% to 0.63%) <0.001
Unknown 7 (0.1) 7 (0.1)
Place of birth U.S.-born 3,331 (64.4) 2,023 (36.2) 1.83 (1.75% to 1.90%) <0.001
Foreign-born 1,825 (35.3) 3,552 (63.6)
Unknown 15 (0.3) 6 (0.1)
Recent arrival in United Statesd Yes 535 (29.3) 1,225 (34.5) 0.59 (0.55% to 0.63%) <0.001
No 1,181 (64.7) 2,111 (59.4)
Unknown 109 (6.0) 216 (6.1)
Site of disease Pulmonary 3,902 (75.5) 3,835 (68.7) 1.20 (1.14% to1.26%) <0.001
Extrapulmonary 788 (15.2) 1,254 (22.5) 0.77 (0.72% to 0.81%) <0.001
the Netherlands (17) also demonstrated that persons with iso-
lates that clustered genetically were younger than those with
unique genotypes. Other risk factors for clustering included
being male, born in the United States, non-Hispanic black, or
homeless; using drugs and alcohol excessively; and having
pulmonary disease and cavitations on chest radiograph, a spu-
tum smear with acid-fast bacilli, and HIV infection. These risk
factors have been observed for TB patients in different com-
munities (12,18,19). The heterogeneity and diversity of the
study population may account for our failure to produce a mul-
tivariate logistic model to predict clustering.
A third of the foreign-born cases were recent immigrants
to the United States, and overall, the percentage of clustered
isolates from foreign-born persons was lower than the percent-
age from nonimmigrants (Figure 3), indicating that at least a
portion of these cases resulted from reactivation of latent dis-
ease or recent infection in the country of origin. In addition,
for foreign-born persons, clustering of M. tuberculosis
increased with the duration of residence in the United States.
These results suggest that recently imported strains of M.
tuberculosis from foreign-born persons may not commonly
spread to U.S. residents or that transmission may be occurring
after a lag time before the imported strains manifest as disease
in contacts. Similar observations have been published in stud-
ies from San Francisco, New York, Switzerland, and Norway
(20–24). These data may also reflect gaps in our knowledge of
M. tuberculosis genotypes in circulation; a comparison of the
U.S. TB genotyping network results with other databases
worldwide may be warranted. 
Logistic regression analysis of the most commonly occur-
ring strains demonstrated that different risk factors were asso-
ciated with specific genotypes. Several genotypes were
associated with ethnic origin (e.g., Asian or Pacific Islander
and Hispanic patients with six and three genotypes, respec-
tively; Table 4). A recent study in Norway showed that several
clusters consisted of patients of the same ethnic origin (23).
An association has also been observed between the patient’s
ethnic origin and IS6110 copy number (25). These results, in
conjunction with additional epidemiologic data, may be useful
in tracking the geographic origin and spread of M. tuberculosis
strains of public health importance (26). 
A small proportion of clustered isolates were from persons
from more than four sites spanning 5 years of study (Table 4).
Figure 2. Average annual incidence of tuberculosis for seven sentinel
surveillance sites and percentage of cases with isolates in genetic clus-
ters, 1996 to 2000. Spearman correlation coefficient and probability of
correlation between incidence and percentage of cases clustered are
given.Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1205
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Table 3. (continued) Comparison of demographic and behavioral risk factors and clinical and treatment outcomes of tuberculosis (TB) case-
patients who have genetically clustered genotypes with factors and outcomes of patients who had unique genotype patternsa
Variableb Clustered (%) Unclustered (%) Relative risk (95% CI) Probabilityc
Site of disease Pulmonary and extrapulmonary 476 (9.2) 492 (8.8) NS
Unknown 5 (0.1) 0
Sputum smear Positive 2,270 (43.9) 2,011 (36.0) 1.22 (1.11% to 1.33%) <0.001
Negative 1,802 (34.8) 1,943 (34.8)
Not done/unknown 1,099 (21.3) 1,627 (29.1)
Chest radiographe Cavitary 1,345 (30.7) 1,172 (27.1) 1.09 (1.04% to 1.14%) <0.001
Noncavitary 2,639 (60.2) 2,826 (65.3) 
Normal 146 (3.3) 118 (2.73)
Not done/unknown 253 (5.8) 211 (4.9)
Total 4,383 4,327
HIV statusf Positive 458 (22.2) 223 (11.8) 1.37 (1.29% to 1.46%) <0.001
Negative 978 (47.4) 847 (44.8) NS
Indeterminate 0 4 (0.2)
Refused 106 (5.1) 138 (7.3)
Not offered 252 (12.2) 354 (18.7)
Unknown 270 (13.0) 323 (17.1)
Total 2,064 1,889
Homeless within past year Yes 370 (7.2) 139 (2.5) 1.55 (1.46% to 1.64%) <0.001
No 4,724 (91.4) 5,370 (96.2)
Unknown 77 (1.5) 72 (1.3)
Resident of correctional facility at diagnosis Yes 190 (3.7) 69 (1.2) 1.55 (1.43% to 1.67%) <0.001
No 4,966 (96.0) 5,503 (98.6)
Unknown 15 (0.3) 9 (0.2)
Injecting drug useg  Yes 312 (6.0) 72 (1.3) 1.73 (1.65% to 1.83%) <0.001
No 4,540 (87.8) 5,231 (93.7)
Unknown 319 (6.2) 278 (5.0)
Noninjecting drug useg  Yes 460 (8.9) 140 (2.5) 1.65 (1.57% to 1.73%) <0.001
No 4,335 (83.8) 5,140 (92.1)
Unknown 376 (7.3) 301 (5.4)
Excessive alcohol useg Yes 948 (18.3) 371 (6.6) 1.61 (1.54% to 1.67%) <0.001
No 3,897 (75.4) 4,893 (87.7)
Unknown 326 (6.3) 317 (5.7)
First-line drugs h Yes 622 (12.1) 755 (13.7) 0.93 (0.87% to 0.99%) 0.016
No 2,718 (53.0) 3,337 (60.5)
Not done 1,748 (34.1) 1,356 (24.6)
Unknown 45 (0.9 66 (1.2)
Total 5,133 5,514
aCI, confidence interval; S.E., standard error.
bOnly factors that had significant differences are shown. 
cProbability of chi-square statistic is shown, except for t-test results from analysis of age from each group.
dForeign-born only; arrived in the United States within 2 years.
eExcludes cases with extrapulmonary TB only.
fCalifornia TB cases not included; ages 15–44 years only.
gExcessive drug or alcohol use within last year.
hFirst-line drug resistance is resistance to at least one of the following: isoniazid, rifampin, ethambutol, or streptomycin. Second-line drug resistance is resistance to one or more of the 
following: ethionamide, kanamycin, cycloserine, capreomycin, para-amino salicylic acid, amikacin, rifabutin, ciprofloxacin, ofloxacin, or other drugs. Testing results for one or more 
of the drugs could have been missing.TUBERCULOSIS GENOTYPING NETWORK
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Table 4. Odds ratios from best-fit logistic regression analyses of the presence or absence of a specific genetic cluster of Mycobacterium 
tuberculosis on demographic, clinical, behavioral, or treatment outcome variables a
Designationc IS6110 copies Spoligotypec N Main effect Odds ratio estimates (95% CI)b Wald pb
00003c 1 777777777760771 40 Asian/Pacific Islander 3.70 (1.51% to 9.02%) 0.004
Age 0.98 (0.96%  to 0.99%) 0.017
Foreign-born 12.4 (3.83% to 39.9%) <0.0001
00129d 1 777777777413771 25 Asian/Pacific Islander 73.3 (17.0% to 315.6%) <0.0001
Extrapulmonary infection 2.57 (1.10% to 6.03%) 0.03
00129d 1 777777774413771 83 Asian/Pacific Islander 282.8 (88.06% to 908.11%) <0.0001
00129d 1 477777777413071 23 Asian/Pacific Islander 6.34 (1.52% to 26.44%) 0.01
Foreign-born 10.4 (1.55% to 70.12%) 0.02
00129d 1 777777777413731 13 Asian/Pacific Islander 13.88 (3.71% to 51.92%) <0.0001
Resistance to first-line drugsd 3.80 (1.22% to 11.86%) 0.02
00129 1 777776407760601 40 Female 2.73 (1.43% to 5.23%) 0.0025
Black, non-Hispanic 3.57 (1.47% to 8.68%) 0.005
Injecting drug use 3.81 (1.81% to 8.03%) 0.0004
00016 2 701776777760601 129 Male 0.58 (0.40% to 0.84%) 0.004
Black, non-Hispanic 10.88 (5.48% to 21.6%) 0.006
00016c 2 777776777760771 82 Hispanic 16.36 (10.15% to 26.37%) <0.0001
00016 2 037776777760601 30 Age 1.03 (1.01% to 1.05%) 0.006
Black, non-Hispanic 7.13 (2.36% to 21.53%) 0.0005
Resident, long-term care facility 3.67 (1.17% to 11.70%) 0.026
00016d 2 777776777760601 175 U.S.-born 3.12 (1.85% to 5.26%) <0.0001
Excessive alcohol use 0.55 (0.37% to 0.83%) 0.0048
00370 3 700036777760731 13 White, non-Hispanic 5.20 (1.52% to 17.79%) 0.0087
HIV positive 5.87 (1.69% to 20.41%) 0.005
Noninjecting drug use 3.74 (1.17% to 12.01%) 0.03
00017d 4 700076777760771 25 Hispanic 4.97 (2.16% to 11.44%) 0.0002
00017d 4 777776777760771 64 Hispanic 15.7 (9.24% to 26.71%) <0.0001
01285 4 777776777760771 20 Resident, correctional facility 8.23 (3.08% to 22.01%) <0.0001
00015 7 28 Black, non-Hispanic 7.04 (1.64% to 30.3%) 0.0087
Injecting drug use 4.84 (2.11% to 11.09%) 0.0002
Excessive alcohol use 2.28 (1.02% to 5.13%) 0.05
00768 9 19 Black, non-Hispanic 11.68 (1.54% to 88.87%) 0.02
Noninjecting drug use 2.77 (1.11% to 6.92%) 0.03
00242d 10 95 Male 2.12 (1.27% to 3.56%) 0.004
Age 0.97 (0.96% to 0.98%) <0.0001
U.S.-born 8.44 (2.63% to 27.09%) 0.0003
Homeless 3.60 (2.16% to 5.98%) <0.0001
Noninjecting drug use 0.46 (0.24% to 0.90%) 0.02
00028 11 70 Black, non-Hispanic 17.57 (5.50% to 56.12%) <0.0001
00159 11 24 Excessive alcohol use 2.76 (1.23% to 6.22%) 0.01
00325 11 20 Age 1.03 (1.01% to 1.06%) 0.01
Excessive alcohol use 3.08 (1.22% to 7.70%) 0.02
00673 11 25 Asian/Pacific Islander 84.6 (19.85 to 361.9%) <0.0001
00757 11 16 Age 0.90 (0.85% to 0.94%) <0.0001
HIV positive 4.86 (1.60% to 14.79%) 0.005Emerging Infectious Diseases  •  Vol. 8, No. 11, November 2002 1207
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Although an in-depth analysis of epidemiologic links was not
possible in this study, we found no evidence of recent trans-
mission between patients with identical genotypes from the
different states (data not shown); this lack of transmission was
also noted in a smaller study in the United States (27). Since
TB transmission is generally considered a local event, these
ubiquitous genotypes may be widespread because of social
factors (e.g., homelessness or alcohol or drug abuse; Table 4).
In addition, these genotypes may represent older, endemic
domestic strains that have been in the United States for centu-
ries and have dispersed more widely throughout the United
States than the more recently imported strains. Further molec-
ular characterization of these genotypes may show additional
differences not detected by RFLP. Nonetheless, the effect of
M. tuberculosis virulence or host factors on the distribution of
these genotypes cannot be ascertained. 
The proportion of strains that were classified into clusters
of identical genotypes (48%) was comparable with proportions
in the Netherlands and Denmark (50%) (2,28), but the propor-
tion was considerably higher than in two other countries (17%
in Switzerland [29]; 20% in Norway [23]). The cumulative
percentage of clustered strains reached a plateau by the end of
the study’s second year (Figure 1), a finding consistent with
other molecular epidemiologic TB studies (2). Increases in
maximum cluster size were anticipated because, as sample
sizes increase with time, the number of isolates in each cluster
would be expected to increase. In addition, higher proportions
of clustered cases were observed for low-band number pat-
terns (Figure 3), which had the maximum cluster size and may
Table 4. (continued) Odds ratios from best-fit logistic regression analyses of the presence or absence of a specific genetic cluster of Mycobacte-
rium tuberculosis on demographic, clinical, behavioral, or treatment outcome variables a
Designationc IS6110 copies Spoligotypec N Main effect Odds ratio estimates (95% CI)b Wald pb
00019c 12 27 Male 3.68 (1.10% to 12.39%) 0.03
White, non-Hispanic 5.4 (2.35% to 11.08%) <0.0001
00372 12 20 Homeless 6.09 (2.43% to 15.20%) 0.0001
Resident, long-term care facility 5.52 (1.535 to 20.0%) 0.009
00035 13 33 Black, non-Hispanic 6.96 (2.3% to 21.0%) 0.0006
Resistance to second-line drugse 40.59 (16.5% to 99.85%) <0.0001
00867 14 20 Black, non-Hispanic 11.68 (1.54% to 88.87%) 0.02
Noninjecting drug use 2.77 (1.11% to 6.92%) 0.03
01284 17 46 Black, non-Hispanic 2.40 (1.22% to 3.57%) <0.0001
Pulmonary disease 0.92 (-0.01% to 1.86%) 0.054
00237c 21 98 White, non-Hispanic 2.80 (1.81% to 4.33%) <0.0001
Excessive alcohol use 2.09 (1.36% to 3.22%) 0.0007
01693 21 29 HIV positive 3.16 (1.39% to 7.18%) 0.006
Injecting drug use 3.08 (1.26% to 7.56%) 0.014
Extrapulmonary disease 3.99 (1.69, 9.42) 0.002
00027 22 78 Black, non-Hispanic 1.74 (1.05% to 2.90%) 0.03
Sputum-smear positive 3.07 (1.75% to 5.39%) <0.0001
aCI, confidence interval.
bOnly genetic clusters that had ≥ 20 isolates were included in the analysis; some samples sizes are <20 because of missing data among independent variables (Wald 95% confidence 
intervals given in parentheses). Only genetic clusters with significant predictors are listed. Age was modeled as a continuous variable.
cThe National Tuberculosis Genotyping Surveillance Network (NTGSN) designation for the IS6110 RFLP pattern is represented; spoligotype octal code designations are presented 
only for those genetic clusters from isolates that had ≤ 6 copies of IS6110.  RFLP patterns and spoligotypes are detailed elsewhere (11).
disolates observed in ≥  4 sites over 5 years.
e First-line drug resistance is resistance to at least one of the following: isoniazid, rifampin, ethambutol, or streptomycin. Second-line drug resistance is resistance to one or more of the 
following: ethionamide, kanamycin, cycloserine, capreomycin, para-amino salicylic acid, amikacin, rifabutin, ciprofloxacin, ofloxacin, or other drugs.
Figure 3. Number of cases with isolates that had unique genotypes
(“not clustered”) and those in genetic clusters for U.S.-born (A) and for-
eign-born persons (B) by number of copies of IS6110.TUBERCULOSIS GENOTYPING NETWORK
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indicate that the low-copy IS6110 patterns are not specific,
even with the addition of spoligotyping. 
The sensitivity and specificity of IS6110 RFLP in molecular
epidemiologic studies have not been quantified and represent a
potential limitation of this study. Although the stability of
IS6110 is relatively high, the half-life of IS6110 RFLP is esti-
mated to be 3–10 years (29–31) based on typing of serial iso-
lates from individual patients. A study of isolates from patients
in confirmed chains of transmission showed little change in
IS6110 patterns (32). Calculation of these rates may be influ-
enced by the duration between time of disease onset and time of
sampling and may be proportional to the effectiveness of the
TB control program (30). Because genotyping results were not
available for 10% of TB cases in this study, estimates of the
degree of clustering and the size of clusters are conservative.
Some unique isolates might have clustered if some of the miss-
ing isolates had been available or if other cases with the same
strain were present outside the study area (33). 
Sentinel surveillance sites defined by artificial boundaries
(i.e., state lines) not entirely representative of TB patients from
the United States were included in this study. More than 90%
of the isolates from patients from the surveillance areas were
genotyped, and these isolates were representative of those cul-
ture-positive patients from the sentinel surveillance areas.
However, 16% of all TB case-patients reported in the United
States were included in these sentinel surveillance sites during
the 5-year study period. In addition, the sentinel surveillance
population had higher proportions of foreign-born persons
than the national average. Because of the propensity of for-
eign-born persons to have isolates with unique genotypes, the
actual rate of clustering may have been underestimated. None-
theless, sentinel surveillance of TB cases has provided a useful
method for documenting genotypes in circulation in the United
States and for identifying risk factor correlates of common
genotypes. 
Annual declines in TB incidence were paralleled by simi-
lar declines in the proportion of cases with genotypes in clus-
ters (Figure 2), a finding consistent with the hypothesis that
decreased clustering is expected with declining incidence (20).
Since effort was similar each year, this association is not likely
to be an artifact related to sample size (i.e., as sample size or
number of cases becomes smaller, the probability of detecting
clusters decreases). These findings underscore the importance
of long-term longitudinal molecular studies and the potential
usefulness of these methods in evaluating program effective-
ness and improving program management.
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